Rocket Pharmaceuticals, Inc.

NASDAQ:RCKT

Biotechnology

Healthcare
$2.11 +1.84%

+$0.06 today

Market cap
$235.60M
Beta
0.47
P/E (TTM)
-1.7
EPS (TTM)
-$1.87
52W Low $2.40High $5.45

Volume 2.49M

Average 3.15M

RCKT Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Rocket Pharmaceuticals, Inc.NASDAQ: RCKT

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares of 112.13M shares rose 1.9% year over year, behind the +12.7% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.9% from the prior quarter. Over 3 fiscal years it compounded at +17.7% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +1.9% toward the trailing-twelve-month pace of +12.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
112.13M+0.9% QoQ
Last fiscal yearDec 2025
111.12M+17.2% YoY
LTMMar 2026
111.46M+12.7% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.9%——
1 year+17.2%——
3-year CAGR+17.7%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
111.12M USD
Year-over-year change
+17.2%
4-year CAGR
+15.1%

Weighted Avg Shares vs competitors

How RCKT compares with its peers on the latest reported figures

  • RCKT's LTM Mar 2026 weighted avg shares of 111.46M shares is the 4th highest of the 10 companies compared; the peer median is 88.66M shares.
  • Its year-over-year change of +12.7% is the 5th highest of 9, against a peer median of +8.5%.
  • Over three fiscal years its annual growth of +17.7% compares with a peer median of +26.3%.
RCKT Competitors Peer median
Weighted Avg Shares for RCKT and competitors
Company Period LTM YoY 3-year CAGR
AUTLAutolus Therapeutics plcLTM Mar 2026266.14M +0.0%+41.0%
QSIQuantum-Si incorporatedLTM Mar 2026201.73M +31.6%+12.4%
ANNXAnnexon, Inc.LTM Mar 2026161.69M +14.3%+41.6%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026111.46M +12.7%+17.7%
SLDBSolid Biosciences Inc.LTM Mar 202698.27M +94.3%+117.4%
DBVTDBV Technologies S.A.LTM Mar 202688.66M -7.8%+3.7%
GALTGalectin Therapeutics Inc.LTM Mar 202664.33M +2.7%+2.5%
AURAAura Biosciences, Inc.LTM Mar 202662.93M +26.5%+26.3%
DSGNDesign Therapeutics, Inc.LTM Mar 202658.14M +2.6%+1.0%
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 202619.77M —+92.6%
Peer median (excluding RCKT) 88.66M+8.5%+26.3%

Competitors are the stored peer set for RCKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue000011.03M
Gross Profit0000(11.03M)
Gross Margin—————
Research & Development125.48M165.57M186.34M171.24M142.02M
Selling, General & Admin41.77M58.77M73.32M101.96M86.5M
Operating Expenses167.25M224.34M259.66M273.21M217.49M
Depreciation & Amortization5.37M6.27M7.1M9.38M11.03M
EBITDA(157.81M)(213.69M)(236.62M)(247.49M)(210.21M)
EBITDA Margin—————
Operating Income(167.25M)(224.34M)(259.66M)(273.21M)(228.52M)
Operating Margin—————
Interest Income3.07M3.89M15.94M18.22M10.62M
Interest Expense5.89M1.91M1.88M1.89M1.89M
Other Income / Expenses(1.82M)2.48M14.06M14.46M5.39M
Income Before Tax(169.07M)(221.86M)(245.6M)(258.75M)(223.12M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(169.07M)(221.86M)(245.6M)(258.75M)(223.12M)
Net Margin—————
EPS (Basic)(2.68)(3.26)(2.92)(2.73)(2.01)
EPS (Diluted)(2.68)(3.26)(2.92)(2.73)(2.01)
Weighted Avg Shares63.24M68.15M84.01M94.81M111.12M
Weighted Avg Shares (Diluted)63.24M68.15M84.01M94.81M111.12M

Rocket Pharmaceuticals, Inc.

NASDAQ:RCKT

Intrinsic Alpha fair value

Locked

Current Price

$2.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.